• Mashup Score: 0

    In an interview with Targeted Oncology, Andrew Kuykendall, MD, discussed the most recent approvals for MPNs, practice changing abstracts presented at ASH 2022, and what he expects to see in 2023.

    Tweet Tweets with this article
    • Recent years have allowed the field of myeloproliferative neoplasms to have several clinical developments, including the novel treatments #ruxolitinib, #fedratinib, and #pacritinib. #mpnsm #MPN #ASH22 | @KuykendallMd @MoffittNews https://t.co/Hqc08z4FMN https://t.co/l1FoEcPan7

  • Mashup Score: 0

    During a Targeted Oncology case-based roundtable event, Jeanne M. Palmer, MD, discussed with participants how the approval of pacritinib for patients with myelofibrosis affects their treatment approach.

    Tweet Tweets with this article
    • During a Targeted Oncology case-based roundtable event, Jeanne M. Palmer, MD, discussed with participants how the approval of #pacritinib for patients with #myelofibrosis affects their treatment approach. | @MayoCancerCare @MayoClinic https://t.co/dwsYvheFIN

  • Mashup Score: 0

    During a Targeted Oncology case-based roundtable event, Jeanne M. Palmer, MD, discussed with participants how the approval of pacritinib for patients with myelofibrosis affects their treatment approach.

    Tweet Tweets with this article
    • During a Targeted Oncology case-based roundtable event, Jeanne M. Palmer, MD, discussed with participants how the approval of #pacritinib for patients with #myelofibrosis affects their treatment approach. | @MayoCancerCare @MayoClinic https://t.co/dwsYvgX4kd